负压封闭引流技术(VSD)治疗足踝部软组织缺损的护理体会

足踝部软组织缺损是临床常见的急性损伤之一，由于该部位皮下组织薄，血液循环差，损伤后易骨质外露，常合并感染，创面很难愈合，对污染严重和部分复合组织缺损而暂时无法进行I期皮瓣和植皮修复的患者，目前我们常采用负压封闭引流技术（VSD）治疗。我科2008年1月～2009年10月对32例足踝部软组织缺损应用负压封闭引流技术治疗，取得了满意疗效，现报告如下。     

四肢软组织静脉畸形的比较影像学诊断

目的比较用于四肢软组织静脉畸形的各影像学检查方法的临床价值。方法收集2009年2月-2014年2月于我院就诊的27例四肢软组织静脉畸形患者,所有患者均行X线平片、超声、CT、MRI及血管造影检查,并对各检查结果进行统计描述,比较各检查的优缺点。结果四肢软组织静脉超声检查可表现大小不等、分布不均、形状不规则的蜂窝或网状液性暗区,软组织中的畸形静脉多表现为可压缩的低回声,明确病变畸形静脉的形态、大小以及范围,并可用于术中动态观察,但该检查方式的病变界限欠清。而MRI检查能够清楚分辨畸形静脉的部位、大小。定位准确,明确病变血管累及范围,并能明确软组织成分,虽相对较昂贵,但对于静脉畸形的诊断有重要的指导意义。结论 MRI以及超声检查对于畸形血管的诊断以及明确病变范围有重要的临床指导意义,值得临床推广及应用。     

HPLC法同时测定磺啶新林胶囊中4个成分的含量

目的:建立同时测定磺啶新林胶囊中盐酸溴己新、盐酸氯丙那林、磺胺甲噁唑和甲氧苄啶含量的方法。方法:采用高效液相色谱法,Ecosil-C₁₈色谱柱（4.6 mm×250 mm,5μm）,以乙腈-0.001 5 mol·L^-1十二烷基硫酸钠的0.1%三乙胺溶液（用磷酸调pH值至3.0）（52:48）为流动相,流量1.0 mL·min^-1,检测波长为215 nm。结果:4个成分的峰面积与浓度的线性关系良好（r>0.999 9）;加样回收率为98.85%⁹9.58%。结论:该方法可用于磺啶新林胶囊中盐酸溴已新、盐酸氯丙那林、磺胺甲噁唑和甲氧苄啶4个成分的含量测定。     

钙剂联合骨化三醇治疗绝经后妇女骨质疏松的临床分析

目的:探讨钙剂联合骨化三醇治疗绝经后妇女骨质疏松的临床疗效。方法:回顾性分析2009年5月至2011年4月广东省揭阳市妇幼保健院收治的68例绝经后妇女骨质疏松患者的临床资料。对照组(34例)服用钙尔奇D,观察组(34例)服用钙尔奇D+骨化三醇,共6~12个月。监测治疗前后骨密度(BMD)、骨钙素(BGP)、血清IL-6、TNF-a变化情况。结果:对照组腰椎侧位(L2-4)BMD、血清BGP、IL-6、TNF-a治疗前后差异无统计学意义(P>0.05);治疗后,观察组腰椎侧位(L2-4)BMD、血清BGP较治疗前明显增加(P<0.01)。观察组治疗后血清IL-6、TNF-a浓度均较治疗前降低(P<0.05)。结论:钙剂联合骨化三醇治疗绝经后妇女骨质疏松疗效肯定,可提高骨BMD、BGD,降低血清IL-6、TNF-a浓度。     

右美托咪定复合瑞芬太尼在软组织射频热凝+拨针治疗中的应用

目的观察右美托咪定复合瑞芬太尼用于软组织射频热凝+拨针治疗的临床效果。方法选择行软组织射频热凝+拨针治疗的患者60例,依麻醉方式分为咪达唑仑复合瑞芬太尼组(A组)和右美托咪定复合瑞芬太尼组(B组),每组各30例。记录给药前(T0)、给药后5 min(T1)、10 min(T2)、30 min(T3)、50 min(T4)各时点心率(HR),指脉氧饱和度(SPO2),无创平均动脉压(MAP),呼吸频率(RR),手术时间,苏醒时间,瑞芬太尼的总用量,麻醉后不良反应及并发症,患者苏醒即刻视觉疼痛评分(VAS)。结果两组RR、SPO2、手术时间、苏醒时间无差异性;与T0相比,两组T1时点的RR、HR、MAP均下降(P<0.05);与A组相比,B组MAP、HR下降(P<0.05),不良反应发生率,瑞芬太尼总用量B组少于A组(P<0.05),患者苏醒即刻视觉疼痛评分(VAS)B组低于A组(P<0.05)。结论右美托咪定复合瑞芬太尼用于软组织射频热凝+拨针治疗,是一种安全有效的清醒镇静镇痛方法,值得临床推广。     

A Multicenter,Randomized,Double-blind Clinical Study on Wufuxinnaoqing Soft Capsule(五福心脑清胶囊) in Treatment of Chronic Stable Angina Patients with Blood Stasis Syndrome

Objective:To confirm the efficacy and safety of Wufuxinnaoqing Soft Capsule(五福心脑清胶囊,WSC)in the treatment of chronic stable angina(blood stasis syndrome).Methods:A multicenter,randomized,double-blind,placebo-controlled trial with superiority test was designed.A total of 240 patients with chronic stable angina(blood stasis syndrome)from multiple centers were randomly and equally assigned to the treatment group and the control group.Based on standard treatment of Westem medicine,the treatment group was given WSC,while the control group was given WSC mimetic,both for 12 weeks.Observed indicators included the efficacy in angina,the efficacy in Chinese medicine syndrome,the withdrawal or reduce rate of nitroglycerin and routine safety indices.Results:After 12-week treatment,the significant effective rate and total effective rate of the treatment group were significantly better than those of the control group(23.5%vs.9.2%,64.7%vs.30.8%),respectively,with statistically significant difference(P0.01).After 12-week treatment,the decreased points and the decreased rate of angina symptom score in the treatment group were better than in the control group(5.1±4.2 points vs.2.8±3.5 points,44.9%±37.2%vs.25.4%±30.7%)respectively,with significant difference(P0.01).After 12-week treatment,the significant effective rate and total effective rate of the treatment group were better than the control group(respectively,30.3%vs.15.0%,67.2%vs.45.0%,P0.01).After 8-or 12-week treatment,the decreased points and the decreased rate of Chinese medicine syndrome score in the treatment group were better than the control group(P0.05 or P0.01).After 12-week treatment,nitroglycerin withdrawal rate and the withdrawal or reduce rate in treatment group were better than the control group(P0.01).On safety evaluation,the incidence of adverse events(7.563%vs.7.500%)and the incidence of cardiovascular events(0.840%vs.0.000%)in the treatment group were similar with the control group,and the difference was not statistically significant(P0.05).Conclusion:In treatment of chronic stable angina(blood stasis syndrome),WSC can reduce angina attacks and consumption of nitroglycerin,decrease angina severity degree,effectively relieve the blood stasis syndromes,such as chest pain,chest tightness,palpitations,dark purple tongue and other symptoms.Besides,adverse events and cardiovascular adverse events in the treatment group and the control group showed no difference.All shows that the drug is safe and effective.[This study was registered in Chinese Clinical Trial Registry(ChiCTR),with registration number:ChiCTR-TRC-14005158.]     

复方枣仁安神胶囊中黄连的定性鉴别和定量分析

目的:建立复方枣仁安神胶囊中黄连质量标准。方法:采用薄层色谱鉴别法对黄连进行定性鉴别,采用UPLC法测定黄连中盐酸小檗碱的含量。色谱条件:色谱柱:Waters Acquity UPLC BEH C18(2.1 mm×100 mm,1.7m);流动相:乙腈-0.05 mo L·L-1磷酸二氢钾溶液(30∶70)(0.5%三乙胺,磷酸调p H值至3.0~4.0);检测波长为345 nm;流速:0.25 m L·min-1;柱温:25℃。结果:在试验条件下,薄层斑点清楚,阴性无干扰,分离效果较好,重复性良好。UPLC方法学考察表明,制剂中盐酸小檗碱在0.25~1.50g范围内与峰面积呈良好的线性关系(r=0.9999),平均回收率为97.56%,RSD=1.54%(n=6)。结论:该方法准确、快速,重复性好,可用于复方枣仁安神胶囊中黄连的质量控制。     

分光光度法测定红花软胶囊中总黄酮的含量

目的：建立红花软胶囊中总黄酮含量的检测方法。方法：采用UV法,在波长360nm处测定红花软胶囊中总黄酮的含量。结果：用芦丁作对照,在4.657～23.285μg/mL范围内线性关系良好,r=1.0000,平均回收率为97.10%（RSD=1.1%,n=9）。结论：该方法准确、灵敏、重现性好,可用于红花软胶囊中总黄酮含量的测定。     

异维A酸胶丸联合红霉素肠溶胶囊治疗难治性痤疮疗效观察

目的：观察异维A酸胶丸联合红霉素肠溶胶囊治疗难治性痤疮的效果。方法：将106例难治性痤疮患者随机均分成两组,治疗组给予异维A酸胶丸联合红霉素肠溶胶囊,对照组给予异维A酸胶丸治疗4周,观察用药后两组临床指标的改善情况。结果：治疗组与对照组总有效率分别为86.79%、67.92%（P<0.05）,临床疗效治疗组优于对照组。结论：异维A酸胶丸联合红霉素肠溶胶囊治疗难治性痤疮安全、有效。